Safety of T-Control for bladder cancer treatments
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a device called T-Control is safe for people receiving chemotherapy or immunotherapy directly into the bladder. It is for patients who need repeated treatments through a catheter.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have bladder cancer that requires treatment put directly into the bladder (intravesical).
- You must be able to have a catheter placed without help from a specialist.
- You must be able to read and understand Portuguese or English.
- You must agree to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.